What Happens to the CRISPR Twins? Their Lives Will … – time.com
Posted: December 4, 2018 at 10:42 pm
For now, theyre known as Lulu and Nana, pseudonyms that are meant to give them some amount of anonymity amid the international uproar over their birth. As the first babies born after their genomes were edited (while they were embryos, by the genetics tool CRISPR) the twin girls, born in Shenzhen, China, are the subject of scientific and public scrutiny that will only escalate as they get older.
He Jiankui, a professor at the Southern University of Science and Technology, stunned the world when he claimed, both in a video posted by his lab and in an interview with a journalist, that he used CRISPR to disable a gene involved in helping HIV to enter healthy cells. By doing so, he gave the resulting edited embryos, including the twin girls, resistance to the virus. Doing so means He violated current guidelines prohibiting using CRISPR on human embryos for pregnancy. For now, Hes claims are only claims, since he has not published his work in a scientific journal for others to review and validate. While he did present his findings at a conference a few days after his YouTube announcement, researchers can only take the data at face value. He says he plans to publish the data, but now that the report has been released to the public, its difficult to predict which journals would accept the manuscript.
The Chinese researchers university denied knowledge of his experiment and said that He has been on leave since last February. Chinese authorities have now suspended Hes work, and Xu Nanping, vice minister of Chinas Ministry of Science and Technology, said Hes study was abominable in nature and violated Chinese laws and regulations, according to the governments Xinhua news.
The reason for the scientific censure boils down to the fact that He preempted a continuing debate over how and when CRISPR should be used in people. The technology, discovered in 2012, provides unprecedented precision and power to edit any genome, including the DNA of people, by snipping out portions of mutated genes and either allowing the genome to repair itself or by providing healthy versions of the gene. But because the approach is relatively new, scientists are still learning about exactly how precise their edits can be, and what some of the potential negative and long term consequences of altering human DNA could be.
Chinese geneticist He Jiankui of the Southern University of Science and Technology in Shenzhen, China, speaking during the Second International Summit on Human Genome Editing at the University of Hong Kong.
SOPA ImagesLightRocket/Getty Images
Nearly all international genetics groups have guidelines prohibiting using CRISPR to edit human embryos and implanting them for pregnancy, as the Chinese researcher did. Experts fully support using CRISPR in cells that cant be passed down from generation to generation, like skin cells or blood cells.
But what He did will forever change the twins DNA. Because he altered their genomes when they were embryos, those changes were picked up by every new cell that the embryos made as they continued to divide and develop, eventually forming the twins. So when the girls are ready to have children, their eggs may contain the CRISPR edits that He gave them, and they could pass on their altered genes to their children and all future generations of children in their lineage.
Having the gene itself is not necessarily a bad thing the edit He made is meant to protect people from getting infected with HIV but the problem is that scientists arent convinced yet that the HIV protection will be the only thing the CRISPR edit did to the twins genomes.
Its not clear, for example, that CRISPR is as precise as researchers would like it to be. It makes mistakes. In some cases, CRISPR may make unintended changes in random parts of the genome, like an autocorrect feature that mistakenly corrects typos to produce an entirely different word. In other cases, it may not make the edits as consistently as needed, so some cells may be edited while others are not, and some cells may even be partially edited, leaving a patchwork result scientists call mosaicism.
According to experts who reviewed some of the data He presented at a conference days after his stunning announcement, they say there is evidence that both girls born with the CRISPR edits showed such signs of mosaicism when they were embryos, meaning they are now likely to have the same mishmash of CRISPRd and unCRISPRd cells in their bodies. That means that they may not even benefit from the resistance to HIV that Hes grand experiment was meant to provide.
Theres also evidence that compromising the HIV gene may have other consequences for example, making people more susceptible to West Nile Virus and possibly the flu.
Its because of these unanswered questions and potential risks that scientists have favored a moratorium on using CRISPR in human embryos meant for pregnancy, at least until they have a better grasp on how CRISPR works and what some of the long term effects of editing might be. While the U.S. National Academy of Sciences in 2017 allowed for the eventual possibility of human babies whose genomes have been edited by CRISPR, it provided strict criteria for how that should happen: under strict monitoring and only in cases where there is no other medical option.
Neither of those criteria were met in the controversial CRISPR study. The university and the hospital where the births took place denied knowledge of Hes work, and the scientific community was blindsided that he had been proceeding with transferring human embryos for pregnancy. The gene he altered also does not represent an unmet medical need among the couples he worked with, only the fathers were HIV positive, meaning they were unlikely to pass on their infection to their children. Whats more, the fathers were on anti-HIV medications, which controlled their infection and make it even less likely they would infect their partners or their children.
In the twins case, what happens when they want to have children? Will they be allowed to have children naturally, and pass on their edited genes and whatever potential side effects might arise from their altered DNA? Or will regulatory or scientific authorities step in and attempt to control whether their genes continue into future generations by requiring the twins to have IVF and only implanting the embryos that do not show signs of the edited gene? Would those regulatory and scientific bodies even have the right to make such a request?
The implications go beyond just these twins, says Dr. Kiran Musunuru, professor of cardiovascular medicine and genetics at University of Pennsylvania Perelman School of Medicine. If we talk about the sanctity of human life, and the inherent dignity of human life, not much has been gained here. These babies were treated as subjects in a grand medical experiment, and we have to believe that they will be studied for the rest of their lives; its sad actually.
In his presentation and in his video, He justified his unorthodox actions by focusing on the personal. He said the father of the twins now feels motivated to find work and care for his family, and that altering the gene will protect future generations from HIV. But HIV experts say that judicious use and distribution of currently available drugs can effectively stop transmission of the virus, without taking such drastic steps of trying an proven genetic procedure and exposing people to its unknown risks.
While their identities are still protected for now, its unlikely the twins will remain anonymous for long. In bypassing ethical guidelines prohibiting the experiment that he conducted, He not only violated basic tenets of responsible scientific inquiry, he also forever changed how the girls will be viewed by society, and ultimately the decisions they make as a result of their involuntary status as the worlds first CRISPR babies.
Contact us at editors@time.com.
See the rest here:
What Happens to the CRISPR Twins? Their Lives Will ... - time.com
- Reviewers of Chinese CRISPR Research: "Ludicrous" and "Dubious At Best" - BioSpace - December 6th, 2019
- Global CRISPR Technology Market Report 2019-2025 with Analysis of Key Companies - Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Horizon... - December 6th, 2019
- There's still a lot we don't know about China's controversial CRISPR babies, including their health status - Genetic Literacy Project - December 6th, 2019
- The Science of Product Messaging: How Unbiased Information on Pesticides, Fungicides, Herbicides, Organics, GMO and CRISPR Can Affect Consumer Buying... - December 6th, 2019
- Global and Regional CRISPR And CRISPR-Associated (Cas) Genes Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breakaway... - December 6th, 2019
- Here's Why CRISPR Therapeutics Jumped 42.2% in November - The Motley Fool - December 5th, 2019
- Chinas CRISPR babies: Read exclusive excerpts from the unseen original research - MIT Technology Review - December 5th, 2019
- Opinion: We need to know what happened to CRISPR twins Lulu and Nana - MIT Technology Review - December 5th, 2019
- Cyrus, the Broad team up to make in vivo CRISPR use safer - FierceBiotech - December 5th, 2019
- 2019: the year gene therapy came of age - FRANCE 24 - December 5th, 2019
- Here's Why Editas Medicine Jumped 45.3% in November - The Motley Fool - December 5th, 2019
- CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, MD - GlobeNewswire - December 5th, 2019
- CRISPR Technology Market - Industry Growth, Analysis, Business Trends, Competitive Landscape, Regional Forecast to 2030 - Media Releases - CSO... - December 5th, 2019
- CRISPR and Cas Genes Market to Reach a Value of US$ 7234.5 Mn by the End of 2026 - News Description - December 5th, 2019
- Still Spinning In The Sand: CRISPR Therapeutics AG, (NASDAQ: CRSP) - Curious Coins - December 5th, 2019
- Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to Its Board of Directors - Financial Post - December 5th, 2019
- Current Trend:: CRISPR Therapeutics AG, (NASDAQ: CRSP) - Ws News Alerts - December 5th, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire - December 2nd, 2019
- Cyrus Biotechnology and CRISPR pioneers team up to boost gene-editing therapies - GeekWire - December 2nd, 2019
- Human Nature film review: Telling the CRISPR story with wit and verve - New Scientist - December 2nd, 2019
- Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology -... - December 2nd, 2019
- CRISPR in Agriculture Market 2019 by Services, Application, Key Players, Size, Trends and Forecast 2025 - Downey Magazine - December 2nd, 2019
- CRISPR vs. Gene Therapy Round 1: What Investors Need to Know - The Motley Fool - November 30th, 2019
- How will CRISPR change and evolve in the future? - Drug Target Review - November 30th, 2019
- Japan and Singapore Grant CRISPR Patents to MilliporeSigma - PRNewswire - November 30th, 2019
- CRISPR Therapeutics to Present at Upcoming Investor Conferences - StreetInsider.com - November 30th, 2019
- New Research: CRISPR and Cas Genes Market Trends And Top Key Companies Profile || [Addgene Inc, AstraZeneca Plc., Bio-Rad Laboratories Inc] - Industry... - November 30th, 2019
- Growth of CRISPR Market in Global Industry: Overview, Size and Share 2019-2024 - Markets Gazette 24 - November 30th, 2019
- New Data From First Human Crispr Trials Shows Promising Results - Forbes - November 19th, 2019
- BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001 - Reuters - November 19th, 2019
- E-CRISPR could be used to rapidly detect viruses - BioNews - November 19th, 2019
- Co-creator of CRISPR lectures about future applications of genome editing technology - Daily Bruin - November 19th, 2019
- CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9... - November 19th, 2019
- BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, CRISPR Therapeutics, Slack Technologies - Nasdaq - November 19th, 2019
- CRISPR Therapeutics among healthcare gainers; Plus Therapeutics leads the losers - Seeking Alpha - November 19th, 2019
- Another step closer to curing cancer and genetic diseases: All you need to know about CRISPR-Cas9 - Firstpost - November 19th, 2019
- UC Davis leads in innovative gene editing research with NIH grants - The Aggie - November 17th, 2019
- Oppenheimer Weighs in on Crispr Therapeutics AG's Q1 2020 Earnings (NASDAQ:CRSP) - DFS Caller - November 17th, 2019
- US cancer scientists on the verge of gene editing breakthrough to treat cancer - The National - November 17th, 2019
- Youve heard of CRISPR, now meet its newer, savvier cousin CRISPR Prime - TechCrunch - November 15th, 2019
- CRISPR's unwanted anniversary - Science Magazine - November 15th, 2019
- CRISPR Could Stop Replication Of Viruses That Cause Illness, Researchers Say : Shots - Health News - NPR - November 15th, 2019
- AMD, Amarin and Crispr are three stocks to watch for potentially higher prices - MarketWatch - November 15th, 2019
- The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO - Lexology - November 15th, 2019
- Science Behind the Scenes: Multiplexed CRISPR and sgRNA Arrays with the Howard Salis Lab | PLOS Synthetic Biology Community - PLoS Blogs - November 15th, 2019
- CRISPR and Cas Genes Market Estimated to Rise at a Lucrative CAGR of 20.1% During 2018-2026 - TheFinanceTime - November 15th, 2019
- CRISPR Used to Silence Crucial Hepatitis B Gene - Medscape - November 13th, 2019
- Modified CRISPR gene editing tool could improve therapies - Drug Target Review - November 13th, 2019
- Global Plant Breeding and CRISPR Plants Market is Expected to Reach USD 21.2 Million by 2025 : Fior Markets - GlobeNewswire - November 13th, 2019
- AI and gene-editing pioneers to discuss ethics - Stanford University News - November 13th, 2019
- CRISPR: the movie - Nature.com - November 12th, 2019
- Editas Medicine Announces Third Quarter 2019 Results and Update - GlobeNewswire - November 12th, 2019
- Q&A: Everything You Need to Know About the Future of CRISPR-Cas9 - Philadelphia magazine - November 11th, 2019
- Technology Networks Explores the CRISPR Revolution: An Interview With Professor Glenn Cohen, World-leading Expert on Bioethics - Technology Networks - November 11th, 2019
- As CRISPR horizons cloud, a startup focuses on the next big thing with powerhouse potential the RNA editing platform - Endpoints News - November 11th, 2019
- Doctors try CRISPR gene editing for cancer, a 1st in the US - NBCNews.com - November 8th, 2019
- A Highly Precise Cas9 Enzyme, SaCas9-HF, Is Added to the CRISPR Toolbox - Technology Networks - November 8th, 2019
- Everything You Need to Know About Superstar CRISPR Prime Editing - Singularity Hub - November 8th, 2019
- Here's Why Crispr Therapeutics Gained 22.8% in October - Motley Fool - November 8th, 2019
- CRISPR Therapeutics AG ($CRSP): Caution Is Advised (2019-11-08) - WCX19 - November 8th, 2019
- Could CRISPR Technology Rise As A Hero In The Era Of Antibiotic Resistance? - Kaiser Health News - October 30th, 2019
- Young scientists urge New Zealand's Green Party to embrace CRISPR for 'sake of the climate' - Genetic Literacy Project - October 30th, 2019
- CRISPR Therapeutics AG (CRSP) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance - October 30th, 2019
- KSQ Therapeutics to Present First Data from its Proprietary CRISPRomics Discovery Engine - Business Wire - October 30th, 2019
- Intellia Therapeutics Presents In Vivo and Ex Vivo Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) - Yahoo... - October 30th, 2019
- When the Target Isn't Really the Target: One Way Cancer Drugs Fall Out of Clinical Trials | DNA Science Blog - PLoS Blogs - October 27th, 2019
- Viewpoint: Why CRISPR embryo editing is not 'morally urgent': No one has to have a child - Genetic Literacy Project - October 26th, 2019
- Phenotypic Screening Advances in Technologies and Techniques - Technology Networks - October 26th, 2019
- Is CRISPR Therapeutics AG (CRSP) Going To Burn These Hedge Funds ? - Yahoo Finance - October 26th, 2019
- Introducing: iPSC Collection from Tauopathy Patients - Alzforum - October 26th, 2019
- CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics - PRNewswire - October 23rd, 2019
- Crispr's next frontier is in-human treatment, says co-inventor - The Business Times - October 23rd, 2019
- CRISPR Therapeutics to buy JV from Bayer - Life Sciences Intellectual Property Review - October 23rd, 2019
- CRISPR scientist wants to edit genes that cause deafness but falls short of permission - International Business Times, Singapore Edition - October 23rd, 2019
- 2019 CRISPR & CRISPR-associated Genes Market to Emerge with Increasing Demand for Drug Discovery with Top Companies Insights - Thermo Fisher... - October 23rd, 2019
- Attractive Stock of Yesterday : CRISPR Therapeutics AG (CRSP) - WEB NEWS OBSERVER - October 23rd, 2019
- At Current Price, Is It Too Late To Buy CRISPR Therapeutics AG (CRSP)? - US Post News - October 23rd, 2019
- Top 10 biotech innovations of all time, including CRISPR, IVF babies - Genetic Literacy Project - October 18th, 2019
- Genetic engineering, CRISPR and food: What the 'revolution' will bring in the near future - Genetic Literacy Project - October 18th, 2019
- CRISPR gene editing raises hopes of easing the pain associated with sickle cell disease - Genetic Literacy Project - October 18th, 2019